Bayer tweaks anti-counterfeiting tactics

A Bayer team from various corporate disciplines assigns anti-counterfeiting features to products based on evaluated risk level. Risk criteria include patient health ramifications, product properties, supply chain considerations and economic drivers, all considered in light of a potential counterfeiting scenario. 

The team then selects security features to incorporate with layout, design and packaging, an anonymous spokesperson tells Securing Pharma. The packaging for one critical medicine has seven security features that nearly assure complete protection against counterfeiting, according to the spokesperson. Most of these features can be seen with the naked eye, according to Bayer, although some require ultraviolet light and decoder templates.

But the effort doesn't stop there. Tie-ins with serialization and traceability efforts come next, followed by use of analytics for physical, chemical and packaging material.

- see the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.